Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

camvest 41 posts  |  Last Activity: Apr 30, 2015 8:27 PM Member since: Dec 28, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • camvest camvest Mar 16, 2015 1:13 AM Flag

    Big money will get behind this as continuous testing confirms its value, if big pharma doesn't like it they will lose out. It happens.

  • Why is OCATA still listed on yahoo finance as Other OTC, instead of NASDAQ

  • Good book out by Steven Druker regarding the FDA and GMO cesspool. Altered Genes and Twisted Truth

  • Good article mentions CCR5 editing being possible functional cure for AIDS and mentions Calimmune's clinical trial:

    " The trial is not the first gene-editing technology to reach human clinical trials — Calimmune in July 2013 treated its first patient in a Phase I/II study using a different gene-editing method, for example — but it is significant because it potentially could lead to a cure, rather than chronic treatment, for HIV.

  • Reference to this article was found on message board for OCAT and ICELL. Mentions Calimmune. Good positive article talking about possible functional cure for AIDS:

    "The trial is not the first gene-editing technology to reach human clinical trials — Calimmune in July 2013 treated its first patient in a Phase I/II study using a different gene-editing method, for example — but it is significant because it potentially could lead to a cure, rather than chronic treatment, for HIV.

  • Reply to

    Residual Glyphosate In Humans

    by md2021d Jan 29, 2015 8:46 AM
    camvest camvest Mar 4, 2015 1:46 PM Flag

    Point is to obfuscate the issue.

  • Check out March 2015 AARP Bulletin story by Peter Jaret "An End to Blindness" Last paragraph on first page mentions OCATA and contains the following quote "The holy grail of research to treat macular degeneration, though, is finding ways to regenerate healthy cells to replace those damaged by disease." Check it out. Stem cells are the holy grail. That's not a bad comparison and AARP Bulletin has a rather large subscribership.

  • camvest camvest Mar 2, 2015 9:45 PM Flag

    Market conditions are changing fast for this new industry and for this company, there is a lot of volatility now with various things being tested and approved for a new paradigm in regenerative medicine, so the company is just reacting to those conditions so to optimize its position in the market. They certainly didn't withdraw the shares anticipating they were going to do worse so they probably are planning to do better. This is an experienced management team so they know what they are doing. I saw a lot of negative comments in the days leading up to the up-listing and the announcement of new patent approvals. Maybe it's just human nature to be apprehensive when you're not getting good news every day.

  • camvest by camvest Mar 2, 2015 12:28 AM Flag

    Wow, major good news, another patent upheld in Europe, article on Benitec web site!!

  • Reply to

    Wise dogs don't bark at the milkman

    by camvest Feb 28, 2015 9:47 PM
    camvest camvest Mar 1, 2015 11:56 PM Flag

    I'm happy to see you've identified the real problem, which is spraying toxic substances on food products, like glyphosate.

  • Wow, major good news, another patent upheld in Europe, article on Benitec web site!!

  • Reply to

    Wise dogs don't bark at the milkman

    by camvest Feb 28, 2015 9:47 PM
    camvest camvest Mar 1, 2015 8:56 PM Flag

    Any type of undercooked food can be contaminated with E Coli. That's not even relevant to what we are discussing. Typical misdirection on your part.

  • camvest camvest Feb 28, 2015 11:13 PM Flag

    Pretty important story, ability to partner programs, I thought this was a fairly important part "In addition to our ophthalmic uses, this platform now gives Ocata the ability to carve out the non-ophthalmic uses and to potentially partner this Restorative ImmunologyTM platform for the treatment of devastating autoimmune diseases, such as Lupus and Crohn’s Disease.” cause there are a lot of potential programs Ocata could partner.

  • Ignoresthefacts says organic food kills people, but common sense tells us that people and animals have been eating chemical free "organic" food for millions of years, it's certainly not killing anybody. A lot of folks including the executives at Monsanto and at present a majority of shareholders don't want to change the status quo because they can't envision a company being profitable producing healthy and sustainable products. Things will change despite the dinosaurs in the industry.

    Truth, like milk, arrives in the dark
    But even so, wise dogs don't bark.
    Only mongrels make it hard
    For the milkman to come up the yard.
    ~Christopher Morley, Dogs Don't Bark at the Milkman

  • camvest camvest Feb 28, 2015 4:51 PM Flag

    Get educated yourself, cracker, or learn how to read. Neither one of my comments says Walmart manufactures anything, and my second comment specifically says " Walmart would be a better place to shop if the put more thought into the design of what they bought". You sound stupid making comments about other people getting educated and you don't even know how to read.

  • camvest camvest Feb 27, 2015 6:37 PM Flag

    My message was above your verbal comprehension threshold. I didn't say I went to Walmart to get top quality and I didn't say the price I expected to pay. The point I made, which was a valid one and I will re-emphasize here since you didn't get it the first time, is that Walmart would be a better place to shop if the put more thought into the design of what they bought, and as the benefit of mass production marketing is that you should get a better product at a lower price.

  • 2 experiences I had at Walmart. I bought a pair of Corey running shoes there. A depression developed right under the ball of the foot that caused my sock to bunch up and become very uncomfortable. So I finally cut open the shoe to see why it was so uncomfortable, not being able to wear it anymore. In the top of the sole material right below where the ball of the foot goes there was a manufactured sideways cut taken out of the material. The lining of the shoe was not sufficient to support my foot without having material beneath so that is where the depression developed and that ruined the entire shoe. The same thing is happening with a pair of Brahma boots I bought there so I'm just waiting for warmer weather to take them apart, but I suspect its the same problem. In my mind, the idea of mass production is to make a better product at a lower price. A third pair of high top insulated boots I bought at the same time had so much stiff insulation stuffed in an unyielding ridge around the top of the boot, it chafed my legs badly and I had to cut the tops of the boots off to wear them. Fortunately I bought the boots at a low enough price so next time I can get a better pair of boots somewhere else. But this looks like planned obsolescence. In other words the product is sold relatively inexpensively to induce you to buy it and to throw it away and not take it back if there is a problem and the manufacturer knows you will get limited use out of the product so eventually you will have to buy another pair. There is a problem with the design of the shoes and somewhere in the Walmart organization there is a problem with whoever is doing the buying, because when you buy product in the massive amounts that Walmart does it should be high quality and inexpensive. In the Walmart of today, it's just cheap, but that's not enough to sell me when the product is unusable.

  • Europe approves Western world’s first stem-cell therapy for rare eye condition
    Good article, could mean approval for Ocata therapies not far off.

  • Don't know if anyone posted this yet, but it might be good news if it happens:
    1/27/2015 Benitec considering partnerships for multiple programs,
    CEO says
    Proprietary Intelligence
    Story Benitec (OTC:BTEBY, ASX:BLT), the Sydney, Australia-based
    company focused on DNA-directed RNAi therapies, has been
    attracting partnership interest over the last 12 months, said
    CEO Peter French.
    “We are having discussions about many of our pipeline
    programs with multiple pharma companies,” French said. He
    declined to disclose which companies have been involved in
    partnership discussions with Benitec. The company is not
    interested in a sale and plans to build a pipeline of programs,
    he said.
    The company’s gene silencing technology, ddRNAI, could
    provide a “single shot cure” for a variety of diseases and
    medical conditions including Hepatitis C, Hepatitis B, drug
    resistant lung cancer, wet AMD (Age-related Macular
    Degeneration) and the orphan genetic disease OPMD
    (oculopharyngeal muscular dystrophy), French said.
    When asked if Benitec had been working with an investment
    bank, French said it had worked with Maxim Investment Bank
    in New York last February to raise AUD 30m from healthcare
    institutional investors and Maxim had also assisted with
    partnership discussions.
    French said the fundraisingn gave the company increased
    visibility in the US and Benitec is now considering whether it
    wants to have a stronger US presence. The company currently
    has a laboratory in San Francisco, but it may also consider
    adding a US-based headquarters and moving its US stock
    listing from the OTC board to one of the major exchanges, he
    said. The company is looking “at a range” of investment banks to assist with the potential exchange move but is willing to hold discussions with additional banks outside of this group, French said. Benitec’s market cap on the ASX is approximately AUD 112m. Benitec’s ddRNAI platform technology introduces a small DNA sequence directly into a cell’s nucleus where it silences unwanted or disease-causing genes which can result in long-lasting, positive therapeutic outcomes. Drugs created from the company’s platform technology have fewer side effects, have a more specific delivery of the therapy, and can have multiple therapies in one molecule, French said. The company’s lead drug candidate, TT-034, is undergoing a Phase I/IIa trial for the treatment of Hepatitis C. This is an “open label dose escalation study” so the company will be reporting results on an ongoing basis, French said. Benitec expects to be reporting data to the FDA in the first half of 2016. TT-034 would be able to eliminate the usual long course of treatment for Hepatitis C, French said, noting that patients often have compliance issues with multiple-dose therapies which can hinder positive outcomes. Benitec now has sufficient funding for the next few years, French said, noting Benitec has a cash balance of approximately AUD 30m. The company has a cash burn of about AUD 9m per year and Australia’s R&D tax incentive program provides the company with “a longer cash runway”, French said. The February 2014 capital raise will enable the company to take TT-034 through the Phase IIb trial, he said. Benitec has in-house programs in the areas of Hepatitis C, Hepatitis B, drug resistant lung cancer, wet AMD and OPMD. It already has licensing agreements with Calimmune for HIV/AIDS, with Regen BioPharma (OTC: RGBP) for cancer vaccines, with uniQure (NASDAQ: QURE) for Huntington’s Disease, with Genable for Retinitis Pigmentosa, and with Circuit for neuropathic pain. The company’s legal advisers are FAL in Australia and DLA
    Piper in the US. by Ilene

  • Reply to

    Benitec news

    by bigbangchester Feb 4, 2015 11:38 PM
    camvest camvest Feb 6, 2015 4:50 PM Flag

    Dr. Chiplin would probably have sold a greater percentage of his shares if he was concerned about the company's progress. The dollar amount of the shares he sold ($45,500) probably represents normal profit-taking. Everybody has expenses. Dr. Chiplin also has options for another 400,000 shares expiring in 2016 at $1.25. Nice, I see Benitec's share price and volume is up today.

ACTC
6.97+0.17(+2.50%)Nov 13 3:59 PMEST